|
Which carcinogenicity study should I use? Automated identification of reliable studies - PUB
|
|
0
|
113
|
June 29, 2026
|
|
🇺🇸 FDA FY26 GDUFA Public Workshop
|
|
21
|
990
|
June 28, 2026
|
|
👨💻 Determination of nitrite and nitrate in pregelatinized starch by ion chromatography
|
|
0
|
223
|
June 26, 2026
|
|
Indian Pharmacopoeia introduces a new General Chapter on Nitrosamine Impurities in its 2022 edition
|
|
4
|
2065
|
June 26, 2026
|
|
Mutagenic Impurities in USP -future looking
|
|
17
|
1658
|
June 26, 2026
|
|
The Future of Bio/Pharmaceutical Analysis 2026 - Nitrosamines
|
|
4
|
330
|
June 26, 2026
|
|
Regulatory Flexibilities and Clarifications: Chemistry, Manufacturing and Control (CMC) Information for Original First in Human (FIH) Phase 1 INDs
|
|
2
|
364
|
June 25, 2026
|
|
NDSRI growth with respect to age
|
|
12
|
570
|
June 25, 2026
|
|
👨💻 Nitrosamines Conversations -Coming Soon! 🎙
|
|
0
|
146
|
June 25, 2026
|
|
Recrystallization can stop nitrosamine formation in ranitidine hydrochloride - PUB
|
|
1
|
254
|
June 24, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
164
|
June 23, 2026
|
|
During analysis NDELA Area observed dropped in standard solution after running sample what could be the reason
|
|
1
|
94
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
210
|
June 22, 2026
|
|
Nitrosamines & Genotoxic Impurities in Pharmaceutical Development and Manufacturing
|
|
3
|
399
|
June 21, 2026
|
|
Advancing Nitrosamine Analysis: USP Frameworks and LC-MS/MS Solutions
|
|
1
|
309
|
June 19, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
291
|
June 19, 2026
|
|
Nitrosamine risk assessment in early clinical development
|
|
0
|
218
|
June 17, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
5636
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
161
|
June 16, 2026
|
|
Calculation of the Maximum Daily Dose (MDD) in Mouthwash Products
|
|
3
|
256
|
June 16, 2026
|
|
Rupatadine related Nitrosamine
|
|
1
|
130
|
June 15, 2026
|
|
EMA - Appendix 1 - Update
|
|
94
|
10425
|
June 15, 2026
|
|
Finasteride NDSRI
|
|
2
|
182
|
June 15, 2026
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
538
|
June 11, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
161
|
June 8, 2026
|
|
Upcoming EMA Q&A for other nitrosocompounds
|
|
3
|
474
|
June 5, 2026
|
|
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines -Pub
|
|
0
|
95
|
June 3, 2026
|
|
👨💻 Expand the analytical toolkit for comprehensive detection of nitrosamines using SIFT-MS
|
|
0
|
134
|
June 2, 2026
|
|
An updated version of Health Canada's Guidance on nitrosamine impurities in medications(Update May 29, 2026)
|
|
0
|
327
|
June 2, 2026
|
|
MS Method Development Criterias?
|
|
1
|
182
|
June 2, 2026
|